GlassScriptPhysician profile
Borislav Kheyson
NPI 1538590161
$903.32
in general payments reported to CMS, 2019-2025
14 companies · $292 in 2025
The $292 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15.00 · 2022: $20.42 · 2023: $80.62 · 2024: $495 · 2025: $292.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $868.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $867.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $374.38 | 2024-2025 | Breztri, Airsupra, Farxiga |
| Hologic Sales and Service, LLC | $93.95 | 2023-2024 | Thinprep 2000 Processor |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $86.09 | 2024-2025 | Xifaxan |
| Exact Sciences Corporation | $64.10 | 2024-2025 | Cologuard Collection Kit |
| Astellas Pharma US INC | $63.53 | 2023-2025 | Veozah |
| Pfizer INC. | $51.92 | 2023-2025 | |
| Radius Health, INC. | $27.98 | 2024 | Tymlos |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $25.98 | 2024 | Lifevest |
| Insmed, INC. | $25.02 | 2024 | Arikayce |
| Revance Therapeutics, INC. | $21.80 | 2024 | Daxxify |
| Allergan, INC. | $20.42 | 2022 | |
| Shionogi INC | $16.76 | 2024 | Fetroja |
| Kowa Pharmaceuticals America, INC. | $16.39 | 2025 | Zoryve |
| Genentech USA, INC. | $15.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Borislav Kheyson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.